BRAINSTORM CELL THERAPEUTICS INC. (BCLI)

AI-Powered SEC Filing Analysis

Quarterly Report Filed: 2026-05-15

Key Insights

Company is heavily reliant on convertible debt financing with multiple convertible promissory notes issued in late 2025 (October, November), indicating significant liquidity constraints and potential dilution for existing shareholders.
Recent private placement activity in February 2026 and subsequent May 2026 offering shows ongoing capital raising efforts, suggesting the company requires continuous funding to sustain operations and development of its cell therapeutics pipeline.
Trading on OTCQB Venture Market indicates loss of listing status from major exchanges, reflecting weakened financial position and reduced institutional investor confidence compared to prior periods.
Multiple short-term loan agreements documented through December 2025 suggest operational cash flow challenges and reliance on bridge financing to meet immediate obligations.
At-the-market (ATM) offering program active through Q1 2026 demonstrates dilutive capital raising strategy, though magnitude of proceeds and market reception cannot be fully assessed from filing structure alone.

Current Report Filed: 2026-05-15

Key Insights

Brainstorm Cell Therapeutics announced Q1 2026 financial results on May 15, 2026, indicating the company continues to operate and report earnings despite trading on the OTCQB market, suggesting ongoing business operations.
The company is headquartered in New York with a contact number on file, demonstrating active corporate infrastructure; however, the limited detail in this 8-K filing suggests the substantive financial information is contained in the press release exhibit rather than disclosed directly.
As a non-emerging growth company, BCLI is subject to full SEC compliance requirements, which underscores the regulatory oversight of this smaller-capitalization cell therapy firm despite its OTCQB listing status.

Current Report Filed: 2026-03-31

Key Insights

Brainstorm Cell Therapeutics Inc. announced its financial results for the year ended December 31, 2025, providing investors with an update on the company's performance.
The company did not provide any specific financial figures or guidance in the 8-K filing, limiting the insights that can be gleaned from the information disclosed.
Without more detailed financial data or commentary from management, it is difficult to assess the significance of this report for investors at this time.

Annual Report Filed: 2026-03-31

Key Insights

Brainstorm Cell Therapeutics' financial results showed significant volatility in 2025, with large fluctuations in revenue, margins, and net income.
The company relied heavily on short-term loan agreements and equity offerings to fund its operations, raising concerns about its long-term financial stability.
Brainstorm's pipeline of cell therapy products is still in development, with no clear timeline for regulatory approval and commercialization, which introduces considerable uncertainty for investors.

Current Report Filed: 2026-02-27

Key Insights

Brainstorm Cell Therapeutics has entered into a $1 million private placement with an accredited investor, with the first closing of $125,000 occurring on February 24, 2026 and up to seven additional closings of $875,000 scheduled to occur by September 25, 2026.
The company has amended its 2014 Stock Incentive Plan and 2014 Global Share Option Plan to increase the shared pool of shares available for issuance by 5,500,000 shares, potentially enabling greater equity-based compensation for officers and directors.
Brainstorm has agreed to file a registration statement to register the resale of the shares and warrants issued in the private placement, providing liquidity for the investor.

Current Report Filed: 2026-02-13

Key Insights

Brainstorm Cell Therapeutics has entered into a $1 million private placement agreement, which provides additional funding for the company's working capital needs.
The company will issue common stock and pre-funded warrants to an accredited investor, with the ability to manage ownership dilution through the use of pre-funded warrants.
Brainstorm has agreed to file a registration statement to register the resale of the securities issued in the private placement, providing liquidity for the investor.

Current Report Filed: 2026-01-09

Key Insights

Brainstorm Cell Therapeutics Inc. (BCLI) has entered into three separate securities purchase transactions, issuing three promissory notes to three institutional investors, totaling over $300,000 in proceeds.
The notes contain various conversion features, default provisions, and other terms that may be dilutive to existing shareholders if triggered.
The financing deals provide the company with additional capital, but indicate potential liquidity challenges and a need for further funding.

Get real-time filing analysis in the app

Download on the App Store

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.